摘要
目的探讨胰腺癌对吉西他滨化疗产生耐药性的相关机理。方法复习近年国、内外相关文献,对介导胰腺癌吉西他滨耐药性的主要基因及信号通路加以综述。结果癌基因c-Src与bcl-XL、NF-κB炎症信号通路、细胞因子IL-1β及NO等与介导胰腺癌对吉西他滨的耐药性密切相关;多药耐药基因MDR1/P-gP与胰腺癌吉西他滨耐药的相关性仍有待研究。结论癌基因c-Src与bcl-XL、NF-κB炎症信号通路等可能成为新的治疗靶点以增加胰腺癌的化疗敏感性;介导胰腺癌化疗耐药的关键基因与中心信号通路尚有待阐明。
Objective To investigate the possible mechanism of chemotherapy. Methods Recent literatures about the genes and signal gemcitabine resistance in pancreatic cancer pathways those play key roles in mediating gemcitabine chemotherapy resistance of pancreatic cancer were collected and reviewed. Results Oncogenes like c-Src and bcl-XL, inflammation pathway of NF-κB, cytokines like IL-1β and NO are closely related with the chemoresistance; the relationship between multiple drug resistance relevant genes like MDR1/P-gP and the resistance to gemcitabine remains to be clarified. Conclusion Genes and pathways like c-Src, bcl-X1, NF-κB, etc. might become new targets to increase the chemotherapeutic sensitivity of pancreatic cancer, however, the mechanism of pancreatic cancer chemotherapy resistance still needs further to be studied.
出处
《中国普外基础与临床杂志》
CAS
2005年第5期530-532,共3页
Chinese Journal of Bases and Clinics In General Surgery
基金
国家自然科学基金(编号:30371389)~~
关键词
胰腺癌
化疗
吉西他滨
耐药性
Pancreatic cancer Chemotherapy Gemcitabine Resistance
